PUT - SPRINTER OPEN END - BIOGEN IDEC | Delayed Deutsche Boerse AG 18:43:10 15/05/2024 BST | ||
| 8.63 EUR | -10.85% |
|
| Current month | -8.42% | ||
| 1 month | -20.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 15/05/24 | 8.63 | -10.85% |
| 14/05/24 | 9.68 | -0.72% |
| 13/05/24 | 9.75 | -1.81% |
| 10/05/24 | 9.93 | -0.60% |
| 09/05/24 | 9.99 | -1.28% |
Delayed Quote Deutsche Boerse AG
Last update May 15, 2024 at 06:43 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV7EKE |
| ISIN | DE000VV7EKE5 |
| Date issued | 29/09/2022 |
| Strike | 327 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.45 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.99 € |
|---|---|
| Lowest since issue | 0.6 € |
| Spread | 0.03 € |
| Spread % | 0.35% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
226.9
USD
Average target price
285.9
USD
Spread / Average Target
+26.02%
- Stock Market
- Certificates
- Certificat
